Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results

Program Goals

T2DM and Patients at CV Risk

A Personalized Approach to Glycemic Targets in the Context of CV Risk

CV Risk and Established Oral Antihyperglycemics

Effect of Metformin on CV Risk Factors: the GIPS-III Trial

AEs Associated With TZDs in T2DM

December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

SAVOR-TIMI 53 (Saxagliptin): Hospitalization for HF

EXAMINE (Alogliptin): Hospitalization for HF[a,b]

TECOS (Sitagliptin): Hospitalization for HF

EMPA-REG OUTCOME: Trial Design

EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-REG: Results for CV Death

EMPA-REG: Hospitalization for HF

ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

LEADER (Liraglutide): Study Design

LEADER: Primary Outcome*

LEADER: CV Death

LEADER: Time to Nonfatal MI and Nonfatal Stroke

LEADER: Hospitalization for HF

LEADER: Microvascular Outcomes

What Explains the Macro- and Microvascular Improvements Observed in LEADER?

LEADER: Overall Summary of AEs

LEADER: AEs Leading to Permanent Treatment Discontinuation

LEADER: Risk for Hypoglycemia

Intensive Glycemic Control Increased All-Cause Mortality (ACCORD)[a]

Association of T2DM With 6 Common CVDs/Events

Conclusions

Abbreviations

Abbreviations (cont)